Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 3, 2016-03 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Aspirin, beta-blocker and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction

By Berger A.K.   Duval S.   Krumholz H.M.  

ACC Current Journal Review, Vol. 12, Iss. 5, 2003-09 ,pp. : 17-17

Elsevier

Access to resources Recommend Favorite

A prospective randomized clinical trial comparing an individual dose of recombinant FSH based on predictive factors versus a ‘standard’ dose of 150 IU/day in ‘standard’ patients undergoing IVF/ICSI treatment

By Popovic‐Todorovic B.  

Human Reproduction, Vol. 18, Iss. 11, 2003-11 ,pp. : 2275-2282

Oxford University Press

Access to resources Recommend Favorite

Comparison of Effects of Low Dose of Spironolactone and a Thiazide Diuretic in Patients with Hypertension Treated with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Type 1 Receptor Blocker

By Yutaka Miyashita   Mifune Mizuo   Kubota Eiji   Itoh Hiroshi   Saito Ikuo  

Clinical and Experimental Hypertension, Vol. 31, Iss. 8, 2009-12 ,pp. : 648-656

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin-Converting Enzyme Inhibitor Prevents Plasminogen Activator Inhibitor-1 Expression in a Rat Model with Cardiovascular Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis

By Katoh M.   Egashira K.   Mitsui T.   Chishima S.   Takeshita A.   Narita H.  

Journal of Molecular and Cellular Cardiology, Vol. 32, Iss. 1, 2000-01 ,pp. : 73-83

Academic Press

Access to resources Recommend Favorite